Paragon Biosciences
Paragon Biosciences, founded in 2010 and headquartered in Chicago, Illinois, is a global healthcare company that develops biopharmaceutical drugs and accelerates biomedical research. The company addresses complex challenges in life sciences by focusing on innovation in areas such as artificial intelligence, gene therapy, synthetic biology, and biopharmaceuticals. Paragon's portfolio includes several subsidiaries, such as Castle Creek Biosciences, Emalex Biosciences, and Harmony Biosciences, among others, and it is actively involved in nurturing new companies within the healthcare sector. Paragon aims to meet diverse medical needs, particularly in therapeutic areas like central nervous system disorders and dermatology, including orphan dermatology.
Castle Creek Biosciences, Inc. is a gene therapy company based in Exton, Pennsylvania, that specializes in developing personalized gene therapies for rare and serious skin and connective tissue disorders. Founded in 2015, the company utilizes a fibroblast technology platform that extracts fibroblast cells from a patient's own skin. This approach allows for the creation of localized therapies tailored to the unique biology of each individual. By addressing the underlying causes of these conditions, Castle Creek aims to improve the lives of patients facing high unmet medical needs in underserved areas.
Emalex Biosciences is a biopharmaceutical company focused on developing innovative treatments for patients suffering from central nervous system disorders, particularly those with limited or no existing treatment options. The company is advancing its investigational medicine, ecopipam, aimed at addressing fluency disorders and Tourette Syndrome. Emalex also collaborates with patient advocacy organizations and medical researchers to enhance the understanding and treatment of rare neurological conditions. Through its efforts, the company seeks to provide effective solutions for individuals affected by these challenging disorders.
Castle Creek Biosciences, Inc. is a gene therapy company based in Exton, Pennsylvania, that specializes in developing personalized gene therapies for rare and serious skin and connective tissue disorders. Founded in 2015, the company utilizes a fibroblast technology platform that extracts fibroblast cells from a patient's own skin. This approach allows for the creation of localized therapies tailored to the unique biology of each individual. By addressing the underlying causes of these conditions, Castle Creek aims to improve the lives of patients facing high unmet medical needs in underserved areas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.